Most people with insurance pay between $0 and a few thousand dollars out of pocket for hepatitis C treatment, even though the medications carry list prices of $25,000 to $90,000 or more. Your actual cost depends on your insurance type, your plan’s drug tier structure, and whether you use copay assistance programs. In many cases, it’s possible to bring your share close to zero.
What Insurance Typically Covers
Hepatitis C drugs are classified as specialty medications, which means they sit on the highest cost-sharing tier of most insurance formularies (usually Tier 4 or Tier 5). For commercially insured patients, health plans absorb roughly 99% of the medication cost based on published analyses of claims data. That still leaves you responsible for a slice that can range from a few hundred dollars to several thousand, depending on your plan’s deductible, coinsurance rate, and out-of-pocket maximum.
If your plan charges coinsurance instead of a flat copay for specialty drugs, you might owe 20% to 33% of the drug’s negotiated price until you hit your out-of-pocket maximum. Because hepatitis C treatment is so expensive, many patients blow through their annual deductible and reach their plan’s out-of-pocket cap within the first prescription fill. Once you hit that cap, the plan covers everything else for the rest of the year. For a plan with a $4,000 or $5,000 out-of-pocket maximum, that number represents your realistic worst-case scenario for the entire course of treatment.
Costs by Insurance Type
Employer-Sponsored and Marketplace Plans
With private insurance, your biggest variable is your plan’s out-of-pocket maximum. Most marketplace plans cap annual out-of-pocket spending, so even with a high coinsurance rate on specialty drugs, you won’t pay indefinitely. A typical 8-week or 12-week course of treatment often triggers enough spending to push you into your plan’s catastrophic coverage phase quickly, after which you owe little or nothing for the remaining fills.
Medicare Part D
Medicare Part D now caps annual out-of-pocket drug spending. For 2025, that cap is $2,000. For 2026, it rises slightly to $2,100. Once you reach that threshold, you pay nothing more for covered prescriptions for the rest of the year. Before reaching the cap, you’ll pay a deductible (around $590 to $615 depending on the year) and then 25% coinsurance during the initial coverage phase. Given the high cost of hepatitis C drugs, most Medicare enrollees will hit the cap with their first fill, making $2,000 to $2,100 the effective ceiling for the entire treatment.
Medicaid
Medicaid generally covers hepatitis C treatment with little to no cost sharing. Access has expanded significantly: 34 state Medicaid programs now require no prior authorization for most patients, which means faster access to treatment. However, some states still impose restrictions. Six states (Alaska, Mississippi, Montana, Nebraska, North Dakota, and West Virginia) maintain substance use restrictions that can delay or complicate approval. Twelve states restrict retreatment for people who were previously treated. If you’re on Medicaid, your out-of-pocket cost is typically $0 to a few dollars per prescription.
Prior Authorization: The Access Hurdle
Even when your plan covers hepatitis C treatment, you’ll likely need prior authorization before filling the prescription. This means your doctor submits clinical documentation proving you need the medication, and the insurer reviews it before approving coverage. The process can take days to weeks.
Historically, many insurers required evidence of advanced liver damage, a liver biopsy, or proof of sobriety before approving treatment. Those restrictions have loosened considerably. Most commercial plans and a growing number of state Medicaid programs no longer require liver damage staging or sobriety as a condition of approval. Still, your insurer may require a confirmed diagnosis through specific lab work, including a quantitative viral load test and possibly genotype testing, before greenlighting the prescription. These diagnostic tests are generally covered as standard lab work under your plan, though they may be subject to your deductible.
How Copay Assistance Can Lower Your Cost to $0
The drug manufacturers behind hepatitis C treatments offer two types of financial help that can dramatically reduce what you pay. Copayment assistance programs are designed for people who already have insurance and can lower or eliminate your deductible, coinsurance, and copay for the medication. Patient assistance programs cover people who are uninsured or whose insurance doesn’t cover the drug, providing medication at no or low cost.
Eligibility for patient assistance programs is typically income-based. Thresholds vary by manufacturer, but common cutoffs range from 300% to 500% of the federal poverty level, which translates to roughly $44,000 to $73,000 in annual income for an individual. You apply directly through the manufacturer, often with help from your prescribing doctor or pharmacy. Once enrolled, coverage lasts 12 months and requires annual re-enrollment.
There’s one important catch. Some insurance plans use copay accumulator programs, which prevent manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum. Under these programs, the insurer tracks manufacturer payments separately from your own spending. This means you could use up all of your copay card benefit and still not have made any progress toward your deductible. When the manufacturer assistance runs out, you’re hit with the full cost-sharing amount. If your plan uses an accumulator program, ask your pharmacist or insurer upfront so you can plan for the potential gap.
The 8-Week vs. 12-Week Cost Difference
The two most commonly prescribed hepatitis C regimens differ in treatment length. One is an 8-week course and the other runs 12 weeks, though some cases require 16 or even 24 weeks. From an insurance perspective, the treatment duration matters less than you might expect for your out-of-pocket cost. Because the medications are so expensive per fill, most patients hit their plan’s out-of-pocket maximum within the first month regardless of which regimen they’re on. An 8-week course simply means fewer total pharmacy visits and a shorter treatment timeline, but your wallet often sees the same impact either way.
Where treatment length does matter is if you’re paying cash or relying on a copay card with a dollar limit. In those situations, fewer weeks of treatment means less total spending.
Realistic Cost Ranges
Putting it all together, here’s what most people actually pay:
- Medicaid: $0 to minimal copays in most states
- Medicare Part D: up to $2,000 in 2025 ($2,100 in 2026), often less with copay assistance
- Private insurance with copay assistance: $0 to $500 in many cases
- Private insurance without copay assistance: up to your plan’s out-of-pocket maximum, commonly $3,000 to $8,000 depending on the plan
The single most effective step you can take is asking your doctor’s office or specialty pharmacy about manufacturer assistance programs before your first fill. These programs exist specifically because the list prices are so high, and they can turn a $5,000 bill into a $0 one. Your prescriber’s office handles these requests routinely and can often get you enrolled within a few days.